Novartis AG (VTX:NOVN) has been given a CHF 80 price target by research analysts at Goldman Sachs Group Inc in a research note issued on Saturday. The brokerage currently has a “neutral” rating on the stock.
Separately, JPMorgan Chase & Co. set a CHF 70 target price on Novartis AG and gave the company a “neutral” rating in a research note on Saturday.
Novartis AG (VTX:NOVN) traded up 0.13% during trading on Friday, reaching CHK 78.75. 5,144,966 shares of the company’s stock were exchanged. The stock’s 50-day moving average is CHK 76.13 and its 200-day moving average is CHK 73.94. Novartis AG has a 12-month low of CHK 67.40 and a 12-month high of CHK 82.80.
About Novartis AG
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.